สังเคราะห์ข้อเสนอเพื่อเสริมสร้างการอภิบาลระบบยา
by วุฒิสาร ตันไชย
สังเคราะห์ข้อเสนอเพื่อเสริมสร้างการอภิบาลระบบยา | |
วุฒิสาร ตันไชย | |
สำนักงานศูนย์วิจัยและให้คำปรึกษาแห่งมหาวิทยาลัยธรรมศาสตร์ | |
2013 | |
สำนักงานศูนย์วิจัยและให้คำปรึกษาแห่งมหาวิทยาลัยธรรมศาสตร์ | |
The Synthesis of Policy recommendations for promoting Good Pharmaceutical Governance has two objectives. First, the report analyzes the risk of Good Governance in Pharmaceutical System in Thailand and, second, proposes the policy recommendation for strengthening Good Pharmaceutical Governance in Thailand due to Pharmaceutical Governance should be developed in three targets; First, Pharmaceutical Governance must provide the medicines that have qualities and coverage for treatments; Second, Pharmaceutical Governance must spends effectively the public budgets and; Third, Pharmaceutical Governance must be deprives of the corruptions. Furthermore, the report uses Good Governance Framework for analysis that consists of Rule of Law, Transparency, Accountability, Participation and Efficiency.
The scope of study of Pharmaceutical Governance in this report focuses on three procedures. First, Drug Registrations are operated by Food and Drug Administration Thailand (Thai-FDA) that officiate about consultations, verifications and permits all medicinal licenses for imports and manufacturing in Thailand. Second, Drug Selection is operated by Sub‐committee on Development of the Essential Drugs List who selects National List of Essential Drug (NLEM). Third, Public Procurement for medicines is operated by public hospitals that regulate by Ministry of Public Health (MoPH).
The results of study discover the risk of Good Governance in Pharmaceutical Governance in three procedures.
1. The risk of Drug Registrations consists of (1) The uncover and obsolete of Pharmacy Act 1967, (2) The appointment and operation of Medicinal Committee, (3) The conflict of Interests of the members of Medicinal Committee and experts, (4) The lack of Experts who verify the documentary medicines, (5) The constraints from budget for operation in Thai-FDA and remuneration for personnel, (6) The discontinuity of medicinal license reviews and (7) The lack of technology promotion and medicinal laboratory for medicinal verification
2. The risk of Drug Selections consists of (1) The appointment and operation of the National Drug System Development Committee, (2) The role and conflict between working group on special experts and working group on Health Economics, (3) The conflict of Interests of the members of committee, sub-committees and working groups, (4) The relation between pharmaceutical industries and the National Drug System Development Committee, (5) The lack of accountable identification to committee and (6) The principles and regulation for Drug Efficiency and Cost-effectiveness of drug
3. The risk of Public Procurement for medicines consists of (1) The lack of drug promotion controls (2) The lack of ethical controls to the members of Pharmacy and Therapeutic Committee (PTC) and health personnel, (3) the standards and regulations of hospitals, (4) the public procurement regulation, and (5) the drug cost estimate determinations
The study discovers a various risk in Pharmaceutical Governance in Thailand therefore the study suggests the policy recommendation for the purpose of strengthening and improvement for Pharmaceutical Governance in six principles, consists of (1) the direction of National Drug Policy determination must defines apparently; (2) the all Acts, Regulations and Policies concerned with Pharmaceutical Governance must be improved well-timed and consults by participatory with all stakeholders; (3) the organizations and committees in Pharmaceutical Governance must make clear their roles and improves a professionalisms in accordance with National Drug Policy; (4) The information and communications technology (ICT) in Pharmaceutical Governance have to connects the insignificant and up-to-date information; (5) The professional ethics of all stakeholders have to promote continuously; and (6) Internal and External Audits must be developed and strengthened. |
|
ระบบอภิบาลยา
การขึ้นทะเบียนตำรับยา กระบวนการคัดเลือกยา บัญชียาหลักแห่งชาติ การจัดซื้อยา ระเบียบการจัดซื้อยา การทุจริตยา |
|
รายงานวิจัย | |
Text | |
application/pdf | |
tha | |
เอกสารฉบับนี้สงวนสิทธิ์โดยสำนักงานศูนย์วิจัยและให้คำปรึกษาแห่งมหาวิทยาลัยธรรมศาสตร์ ห้ามทำซ้ำ คัดลอก หรือนำไปเผยแพร่ตัดต่อโดยมิได้รับอนุญาตเป็นลายลักษณ์อักษร | |
สงวนสิทธิ์ในการเข้าถึงเฉพาะบุคลากรของมหาวิทยาลัยธรรมศาสตร์ | |
https://repository.turac.tu.ac.th/handle/6626133120/23 |
This item appears in the following Collection(s) |
|
Collections
|